Integrating Practice with Precision: A Quantitative HER2 Protein Assay Developed for Clinical Application in Trastuzumab Deruxtecan Treatment Guidance - Scorecard - MDSpire

Integrating Practice with Precision: A Quantitative HER2 Protein Assay Developed for Clinical Application in Trastuzumab Deruxtecan Treatment Guidance

  • By

  • Junmei Hao

  • Xiaochun Fei

  • Fangfang Zou

  • Qian Hu

  • Linlin Du

  • Liya Yu

  • Xuanye Bai

  • Shasha Bi

  • Qinghua Cao

  • Weishan Chen

  • Qun Dai

  • Tingting Guo

  • Hai Huang

  • Wenwei Jiang

  • Baohua Li

  • Lixia Li

  • Jingjing Liu

  • Tong Liu

  • Xiaoqin Liu

  • Jiahong Lyu

  • Yue Pan

  • Xiaoqing Shao

  • Fangrong Tang

  • Tingting Wang

  • Cuiping Zhang

  • Yongcun Zhu

  • Job Tien Chiang Liu

  • Nicole Salazar

  • Shukun Zhang

  • Jiandi Zhang

  • Xiaosong Chen

  • Chaofu Wang

  • April 27, 2026

  • 0 min

Share

Clinical Scorecard: Integrating Practice with Precision: A Quantitative HER2 Protein Assay Developed for Clinical Application in Trastuzumab Deruxtecan Treatment Guidance

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with invasive breast cancer categorized as HER2 IHC 0 and 1+, with emphasis on the clinical implications of this distinction.
Care Setting

Key Highlights

  • AUC

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • S
      • p
      • e
      • c
      • i
      • f
      • y
      • t
      • h
      • e
      • r
      • e
      • c
      • o
      • m
      • m
      • e
      • n
      • d
      • e
      • d
      • f
      • r
      • e
      • q
      • u
      • e
      • n
      • c
      • y
      • o
      • f
      • H
      • E
      • R
      • 2
      • a
      • s
      • s
      • e
      • s
      • s
      • m
      • e
      • n
      • t
      • s
      • a
      • n
      • d
      • t
      • h
      • e
      • m
      • e
      • t
      • r
      • i
      • c
      • s
      • t
      • o
      • b
      • e
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • e
      • d
      • .

      Risks

        Patient & Prescribing Data

        Patients with invasive breast cancer categorized as HER2 IHC 0 and 1+.

        QDB assay provides a quantitative approach to differentiate HER2-low from HER2-0, enhancing treatment guidance.

        Clinical Best Practices

        • add

        References

        Original Source(s)

        Integrating Practice with Precision: A Quantitative HER2 Protein Assay Developed for Clinical Application in Trastuzumab Deruxtecan Treatment Guidance

        • by Junmei Hao, Xiaochun Fei, Fangfang Zou, Qian Hu, Linlin Du, Liya Yu, Xuanye Bai, Shasha Bi, Qinghua Cao, Weishan Chen, Qun Dai, Tingting Guo, Hai Huang, Wenwei Jiang, Baohua Li, Lixia Li, Jingjing Liu, Tong Liu, Xiaoqin Liu, Jiahong Lyu, Yue Pan, Xiaoqing Shao, Fangrong Tang, Tingting Wang, Cuiping Zhang, Yongcun Zhu, Job Tien Chiang Liu, Nicole Salazar, Shukun Zhang, Jiandi Zhang, Xiaosong Chen, Chaofu Wang

        • April 27, 2026

        Related Content

        Multimodal feature fusion model for breast mass malignant risk stratification

        Artificial intelligence improves risk stratification for breast cancer recurrence and mortality in women exposed to pesticides: a call for reassessment of stratification criteria

        MIT president: Why so many optimistic scientists are losing heart